| abstract |
Disclosed is a pharmaceutical composition comprising a formulation principle that stabilizes the amorphous form of Imatinib mesylate and amorphous Imatinib mesylate (4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino-)phenyl]-benzamide), optionally together with at least one pharmaceutically acceptable carrier, wherein the formulation principle is a solid dispersion. The form is preferably a gelatine capsule or a tablet. |